Skip to main content
. 2019 Dec 4;11(12):1938. doi: 10.3390/cancers11121938

Figure 1.

Figure 1

Analysis of cfDNA and tumour tissue in patients with solid tumours: (A) tissue biopsies and cfDNA samples of patients with primary or metastatic tumours are processed for detection of specific somatic genomic alterations (SGAs). The concordance rate between cfDNA and primary tumour or cfDNA and primary and metastatic tumours can be evaluated (B) A summary of factors affecting concordance rates between cfDNA and tumour tissue, 1o: primary tumour, 2o: secondary (metastatic) tumour.